Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. Lopinavir potently inhibited wild-type and mutant HIV protease (Ki = 1.3 to 3.6 pM). Lopinavir (ABT-378) also produced negligible or weak inhibition of human CYP1A2, 2B6, 2C9, 2C19 and 2D6. Lopinavir (ABT-378) blocked the replication of laboratory and clinical strains of HIV type 1 (50% effective concentration [EC50], 0.006 to 0.017 microM), and maintained high potency against mutant HIV selected by ritonavir in vivo (EC50, 50-fold after 8 h.
|Solubility (25°C)||DMSO 110 mg/mL
Ethanol 100 mg/mL
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Weemhoff JL, et al. J Pharm Pharmacol. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
 Sham HL, et al. Antimicrob Agents Chemother. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
|Related HIV Protease Products|
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM.
WAY-300700 is a HIV-1 non-nucleoside reverse transcriptase inhibitor.
WAY-613473 has inhibition of HIV-I replication
Cabotegravir, also known as S/GSK1265744 or GSK744, is potent HIV integrase inhibitor.
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.